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The detailed understanding of the mechanism of 
cell proliferation and its regulation is still a futu re 
goal of cell biologists. The science of molecular 
biology has led to enhanced understanding of life 
proces es, particularly in prokaryotes [1]. Prokar-
yotic molecular biology has developed exponen-
tially because bacteria are orders of magnitude less 
complex than eukaryotes and can be easily grown 
and genetically manipulated. However, progress In 
the molecular biology of eukaryotes is increasing as 
one begins to apply the lessons learned from 
prokaryotes to eukaryotic systems . That the use of 
technique of molecular biology to tudy mech-
anisms of cellular proliferation in eukaryotes repre-
sents a reasonable approach has been amply docu-
mented by the appearance of the monograph 
Control 0/ Proliferation in Animal Cells in 1974 [2]. 
T HE ,ELL CYCLE 
The concept of the cell cycle derives from the 
work of Howard and Pelc, who showed in 1953 that 
proliferating eukaryotic ce"lls synthesize D A at a 
specific time in their life span [3 J. ThiS pOint 10 the 
life of a cell where DNA is synthesized has been 
termed S phase and all other cell cycle parameters 
are defined relalive to it. Thus G 1 (Gap 1) repre-
sents the time from the initial stimulus for the cell 
to enter the cycle to the time that DNA synthesis 
or S phase commences. whereas G, (Gap 2) is the 
time between the cessation of DNA synthesis and 
the beginning of mitosis (M) (Fig.1. Some c,:lls 
such as neurons. which do not normally dIvIde 
during their lives, are never in the cell cycle and 
are said to be "term in ally differentiated ." Other 
cells retain some potential for division (e_g., resting 
lymphocytes) and are said to be in the cell cycle 
state of Go [4.51. The concept of a cell cycle lmphes 
a "proliferative program" and this proliferative 
program will be the focus of this review. 
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Abbreviations: 
Con-A: concanavalin A 
cAMP: cyclic adenosine monophosphate 
cCMP: cyclic cytidine monopbosphste 
cGMP: cyclic guanosine monophosphate 
FGAR: form ylglycineamide ribonucleotIde 
M: mitosis · 
PRPP: phosphoribesyl pyrophosphate 
THE PROLIFERATIVE PROGRAM 
The proliferative program in its entirety defines 
all the events that take place during the cell cycle 
and result in progeny cells. Since a detai led 
discussion of these events is beyond the space 
limitations of thi paper, see, Baserga [4] and 
Mitchison [5] for detailed reviews. 
During Go a signal is perceived by the cell which 
leads to its commitment to the cell cycle and 
entrance into G I. In G 1. the cell prepares for the 
proliferative demands by synthesizing ribosomal 
RNA. phosphorylating histones. making new 
enzymes such as ornithine decarboxylase. increas-
ing substrates necessary for proliferation, and in 
general preparing t he cell for phase. Some of 
these events have been diagrammed in the Figure. 
S phase follows G I. and D~A synthesis as well as 
histone synthesis is achieved during thi period. In 
Gz. components necessary to milo is and cytokine-
sis are made so that mitosis can occur in M pha e. 
The progeny cells can either recycle. leave the 
cycle to lerm inally differentiate. or enter the Go 
component of the cycle. 
The study of regulatory phenomena encountered 
in the cell cvcle ideallv requires a model system 
capable of e~periment~l manipulation. A cell par-
ticularlv amenable to such studies is the lym-
phocyt~. Lymphocytes are normally resting cells 
which can be stimulated by agents known as 
mitogens or lectins to enter [he cell cycle (for a 
review. see [6]). This lectin stimulation allows one 
to study the cellular events occurring wben cells 
are stimulated to leaw Go and become committed 
to the cell cycle . 
In our laboratory, we have developed a serum-
free mouse spleen lymphocyte system in which we 
can stud\· the Go - S transition. unencumbered by 
the unce~tainties usually imposed on such systems_ 
by employing serum with its collection of heteroge-
neous undefined proteins. This lymphocyte system 
when stimulated by concanavalin A (Con-A), a 
plant lectin, synthesizes D T A at a rate of 500- to 
1 OOO-fold !lreater than resting or unstimulated c~lls [7] . DNA synthesis commences about 24 hr 
after lectin addition, in agreement with the previ-
ously published work of Loeb and Agarwal [8 J. 
CYCLlC l\\jCLEOTlDE' A:\D THE LYMPHOCYTE 
SYSTEl\oJ 
T he system described above can be used to probe 
potential activators or inhibitors of cell cycle 
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F,G. The proliferative program and cell cycle as 
descr ibed in the text. 
commitment by asking whether addition of such 
compounds will directly stimulate DNA synthesis 
or inhibit lectin-stimulated DNA synthesis. Had-
den et al [9) reported that cyclic guanosine mono-
phosphate (cGMPl rapidly increased after an ad-
dition of lectin to a lymphocyte system conta ining 
serum. Thi observation prompted us to enquire 
whether cGMP or its more permea ble derivatives, 
dibutyryl cGMP or 8-bromo-cGMP could bypass 
the lectin signal. cGMP and its derivat ives proved 
t.o be weak mitogenic agents and led to a 10-fold 
increase in D A synthesis [7,10 ). Simultaneous 
autoradiographic study showed that lectins stimu-
lated 50% of the lymphocytes to incorpora te 
['HyrdR into nuclear DNA, and 8-bromo-cGMP 
resulted in a 1 to 2% st imulation of the lymphocyte 
population to undergo nuclear D A synthesis [7). 
Both lectin-mediated and cGMP-mediated lym-
phocyte st imu lation of D A synthesis were in hi b-
ited by addition of d ibutyryl cAMP (cyclic adeno-
sine monophosphate l concom ita nt with the stimu-
latory agent [7 ). 
Imidazole is an agent which is t hought to raise 
endogenous levels of cGMP [11 J. In the system 
described above, imidazole increased 0 A synthe-
sis slightly but only in the presence of maximal 
stimulatory doses of Con-A. The st imulat ion by 
imidazole occurred only at 10 - 3 M and did not 
occur when the drug was added by itself or at 
submaximal stimulatory concent rations of Con-A 
(Tab. 0. This result may relate to recruitment of 
subpopula tions of lymphocytes by Con-A- primed 
lym phocytes. Such lectin- timulated cells are 
known to release lymphokines which lead to fur-
ther sti mul ation of other uncommitted cells [12). 
Prostaglandins are lipid moieties which appear 
to function in concert with cyclic nucleotides [1 31. 
When lymphocytes are incubated in t he presence 
of prostaglandins, no stimulation occurs. However, 
prostaglandins of the E series inhibited Con A-
induced lymphocyte stimulation, whereas prosta-
glandins of the F series stimulated Con A-treated 
lymphocytes. The explanation for this ohservation 
may be the same a that described above, and 
fu rther audioradiographic studies designed to test 
this hypothesis are in progress. 
Thus, we appear to be looking at two classes of 
cell cycle stimulatory agents; primary stimulators 
such as lectins and cGMP and secondary stimula -
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tors such as imidazole and prostaglandins. Another 
interesting compound that appears to be a second-
ary stimulator is somatomedin. Somatomedin is a 
factor found in serum after stimulation by growth 
hormone [14 ). A species of dwarf mice exists which 
does not contain somatomedin and shows a dimin-
ished immune response [15). In our hands, soma-
tomedin enhances Con A-mediated lymphocyte 
activation but alone has no effect. Of further 
interest is the fact that addition of somatomedin to 
Con A-treated cells inhibited by cAMP results in 
loss of the inhibition (Tab. II) [16]. The mecha-
nism of this inhibitory reversal. as well as the 
action of somatomedin as a secondary stimulator, 
is under study at this time. Similar findings have 
been obtained using somatomedin in a human 
peripheral blood serum-free lymphocyte system 
[17 ]. 
cycur PYREvllD]:\E M01\OPHOSPHATES .~:\D 
CELL PROLlF'ERATIO:-' 
Cyclic cytidine monophosphate (cCMP) has 
been reported to be present in leukemia cells by 
Bloch (18) and in bacteria cells by Ishiyarna [19]. 
In our hands. cCMP led to s imilar increases in 
D A synthesis as did cGMP [20J. The mitogenic 
effect of cCMP was inhibited by dibut.y ryl cAMP 
TABLE I. Effects of imidazole on Con A -stimulated purine 
biosy nthesis and DNA synthesi.< 
Experiments were performed as described in Cham -
bers et al i7]. Purine biosynthesis was measured as a 
function of the incorporation of I"C ]glyci ne (l )lCi/ml) 
into FGAR in the presence of azaserine . Cells were pulsed 
with I"C jglyc ine 20 hr after indicated addition for a 
period of 90 min. D:\,A synthesis was measured as 
descr ibed [7] 40 hr after indicated add ition. and pulsed 
with ['H ITdR (5 ~ Ci/ml) for 2 h r. 
Addition 
Experi ment #1 
1. "one 
2. 0.25 ~ g/ml Con -A 
3. 10 - ' M Imidazole 
4 . 10- ' M Imidazole 
5. 0.25 )l g/ ml Con-a 
+ 10 - 3 M imidazole 
6. 0.25 )lg/ ml Con-A 
+ 10- ' M imidazole 
Experiment #2 
7. None 
8. 0.05 )lg/ ml Con-A 
9. 0.25)lg/ ml Con-A 
10. 10- ' M Imida zole 
11. 0.05 I' g/ ml Con-A 
+ 10 -' Mimidazole 
12. 0.25 )lg/ ml Con-A 
+ 10 - ' Mimidazole 
Ra t e~ or 
I'H rrdR 
11l('lJrpOra Lion.:! 
t ('pm/ 10' celts , 
1.013 
25.349 
556 
556 
36.246 
25.485 
199 
7.303 
41,185 
114 
5,287 
50,1 68 
• Zero ti me not subtracted. 
Rate!" ot 
I" ('WCAR 
accumulation 
Icpm /1 ()' cells I 
96 
2.428 
12 
72 
4.072 
2.100 
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T"BLE n. Somatomedin-stimulated and 
mitogen-stimulated lymphocyte actiuation 
Cells were treated as in 17 J and legend to Table 
except that cells were pulsed with ['H rrdR for 3 hr. 
(Partially purified somatomedin was supplied by Dr. E. 
M. Spencer.) 
Addition 
Resting cells (mouse spleen lym· 
phocytes ) 
Con-A (Q.5I'g/mll 
Con-A + dibutryl cAMP (5 x 10- ' 
M) 
Con-A + somatomedin (0.5 U) 
Con-A - dibut ryl cAMP + soma-
tomedin 
DNA synthesis 
Il'H j'fdR inc . 
cpm/5 " lO·cetls ~ 
100 
63,000 
3,300 
100.000 
21.000 
in the same manner as that described earlier for 
cGMP. Additionally, cCMP has similar effect to 
cGMP in its ability to inhibit a cAMP-dependent 
cell-free DNA-directed protein synthesizing sys-
tem for tl-galactosidase derived from Escherichia 
coli (unpublished observations). Thus ceMP 
seems to act similarly to cGMP in biologic systems 
derived from both eukaryotes and prokaryotes. 
The cyclic nucleotide system has been termed the 
"metaboli c code" by Tomkins 121 J because these 
compounds act to regulate metabolic pathways. 
The results described above indicate that just as in 
th e genetic code G is complementary to C. a 
functional complementarity exists in the meta-
bolic code such that cGMP is equal to cCMP {20J. 
MOLEC"lILAH E\'E\TS I:" CE LL PROLIFERATIO!\ 
The stud~' of cells synthesizin!! D:\A represents 
study of a process rather than a cellular event since 
DNA svnthesis is the culmination of a number of 
tempor-ally organized cellular events . We have 
examined a number of G I e\'ents in the lymphocyte 
system in order to further understand the regula-
tory phenomena of cell proliferation in eukaryotic 
genetic expression. 
RNA synthesis. The studies of Pogo et al {22 J. 
Johnson and Hadden 1231, and Cooper [241 show 
that an increased incorporation of widine into 
RN A occurs soon after the addi tion of lectins to 
lymphocytes. Preliminary experiments in our labo-
ratory are in agreement with these results. Ribo-
somal RNA appears t.o be the species of RNA that 
is initially made and its synthesis appears inde-
pendent of cAMP inhibition. However, about 8 hr 
after Con-A stimulation, a poly A-rich R A 
appears to be increased in stimulated cells . This 
species is not characteristic of ei ther resting cells or 
cells treated with Con-A in the presence of cAMP 
(unpublished observations). Thus, it would appear 
that cells first make ribosomal RNA necessary for 
an increased synthesi of ribosomes characteristic 
of the proliferating state. Subsequent to the manu-
facture of ribosomes, the cells begin to make a 
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species of R A characteristic of messenger R A. 
Such a situation is consistent with an orderly 
programmed proliferative activation in that a cell 
would first make ribosomes and then message 
enabling their use. 
Purine biosynthesis. We have noted previously 
that one of the events occurring in G I is the 
synthesis of substrates necessary to the prolifera-
tive program. An example of such substrates are 
purines which are obligatory substrates for RNA 
synthesis, DNA synthesis, and compounds neces-
sary for energy such as ATP, GTP, and other 
cofactors. Accordingly, we studied purine biosyn-
thesis and found that it increased 10- to loo-fold in 
Con A-stimulated lymphocytes, relative to resting 
cells. In the presence of dibutyryl cAMP, this 
increase in purine biosynthesis was lnhibited. 
Purine biosynthesis began 8 hr after lymphocyte 
activation and was increased 2-fold by addition of 
either imidazole or dibutyryl cGMP -in the pres-
ence of lectin (see Tab . I and [7]). Since d ibutyryl 
cGMP was shown to stimulate only 1 % of cells, a 
doubling of purine synthesis with an enhancement 
of DNA synthesis of 38 to 50% indicates that 
increases in purine synthesis did not appear to be 
rate limiting for DN A synthesis. In other words. 
one can sti m ulate purine synthesis by a greater 
factor than is reflected by subsequent increases in 
DNA synthesis. Such an observation could be 
explained by the presence of a rate-controlling step 
distal to purine bio ynthesis. tudies relating to 
this hypothesis are in progress. 
Phosphoribos\ { pYrophosphate IPRPPI ynthe-
tase. An increase in purine biosynthesis implies 
either an activation of preexisting enzymes in the 
purine pathway, an increase in concentration of 
these enzymes. or both. The rate-limiting step in 
purine biosynthesis in a eukaryolic cell has re-
cently been shown to be related to the level of 
PRPP in the cell 125]. In addition. PRPP is 
necessary for pyrimidine bio ynthesis as well as 
purine biosynthesis . Since PRPP appears to be a 
central compound in controlling the purine and 
pyrimidine metabolic pathway. we measured the 
level of the requisite enzyme for its synthesis. 
PRPP svnthetase. as a function of time and lectin 
stimu lation. PRPP s~'nthetase increased linearly 
after an 8-hr lag period . That the enzyme was 
apparently synthesized de novo was shown by the 
fact that the addition of the protein synthesis 
inhibitor pactimycin resulted in prompt cessation 
of induction of PRPP synthetase . When the 
enzyme assays were carried out in the presence of 
cGMP, enzyme activity of the stimulated species 
increased 2- to 5-fold. Enzyme induction was 
inhibited bv cAMP, and activation of PRPP syn-
thetase mediated by cGMP was likewise inhibited 
[7]. We have surveyed a number of tissues for the 
presence of cGMP-activatable PRPP synthetase 
and find its presence characteristic of proliferating 
or growing cells (e.g., present in lymphoblasts and 
lymphosarcoma cells, absent in quiescent Iympho-
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cytesl. Green and Martin [25] purified PRPP 
synthetase free of protein kinase activity, from rat 
hepatoma cells (HTC), and found that PRPP 
synthetase responds to concentrations of cGMP as 
low as 10- 9 M [26], These data , in conjunction with 
ours, make it likely that cGMP acts as an allo-
stearic eflector of PRPP synthetase by decreasing 
the apparent K", for ATP. It is reasonable to 
speculate that other enzymes characteristic of the 
growing state may also be cGMP-mediated. Ob-
viously, we a re concentrating some effort on this 
hypothesis . 
Thus, it would appear that cGMP can act not 
only as a weak mitogen but also as an activat.or of 
newly synthesized enzymes characteristic of cell 
growth in proliferation. Such a situation allows for 
efficiency in increasing catalytic capacity of an 
enzyme to meet the demand of the proliferative 
program. In the case of PRPP synthetase, a lO-fold 
increase in de novo enzyme production would lead 
to a 50-fold increase in catalytic capability. 
CO:\CLUSIOl\'S 
It is now possible to design systems in which one 
can carefully study the molecular biology of cell 
proliferation. We ha\'e employed a serum-free 
mouse spleen lymphocyte system to study some of 
the molecular events occurring during the G ,-S 
phases of the cell cycle. Through the use of this 
system, we have been able to show int.eractions of 
regulatory molecules such as cyclic nucleotides. 
prostaglandins. etc. to activatE' or deact ivate the 
proliferative program. We also have been able to 
differentiate events from processes and , through 
such studies, have found the presence of a speci-
fic PRPP synthetase, activatable by cGMP. which 
may be an example of a class of enzymes specifi-
cally adapted fo r proliferation. It is almost certain 
that future developments in the study of cell pro-
liferation will use analogous systems from other 
cell types to decipher the enigmas of cell prolifera-
tion. It is hoped that this type of approach will yield 
new understanding of dermatologic problems such 
as psoriasis, neoplasia. and wound healing. 
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